{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7138,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/16",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-16",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "why_now",
      "function": "argue_timing",
      "notes": "Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. competitors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/17",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-17",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        },
        {
          "to": 21,
          "from": 17,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "937d5537-d54e-4e3a-a66e-a14f52ce0de8",
          "evidence": "Discussion of NXC-201 entering large markets at a pivotal moment",
          "position": 2,
          "objective": "Explaining the timing of NXC-201's entry into the market",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.6,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/18",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-18",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        },
        {
          "to": 21,
          "from": 17,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "937d5537-d54e-4e3a-a66e-a14f52ce0de8",
          "evidence": "Discussion of NXC-201 entering large markets at a pivotal moment",
          "position": 2,
          "objective": "Explaining the timing of NXC-201's entry into the market",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.6,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/19",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-19",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        },
        {
          "to": 21,
          "from": 17,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "937d5537-d54e-4e3a-a66e-a14f52ce0de8",
          "evidence": "Discussion of NXC-201 entering large markets at a pivotal moment",
          "position": 2,
          "objective": "Explaining the timing of NXC-201's entry into the market",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.6,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/20",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-20",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        },
        {
          "to": 21,
          "from": 17,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "937d5537-d54e-4e3a-a66e-a14f52ce0de8",
          "evidence": "Discussion of NXC-201 entering large markets at a pivotal moment",
          "position": 2,
          "objective": "Explaining the timing of NXC-201's entry into the market",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.6,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a red dashed box to highlight the core clinical data rows for comparison.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/21",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-21",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        },
        {
          "to": 21,
          "from": 17,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "937d5537-d54e-4e3a-a66e-a14f52ce0de8",
          "evidence": "Discussion of NXC-201 entering large markets at a pivotal moment",
          "position": 2,
          "objective": "Explaining the timing of NXC-201's entry into the market",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.6,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart demonstrates deepening clinical responses over time for NXC-201 therapy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/22",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-22",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The table uses a red dashed box to highlight the core clinical data rows.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/23",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-23",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide highlights specific safety data points for a competitor product to establish a benchmark.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/24",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-24",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a structured table format to map clinical trial progress against specific disease indications.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/25",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-25",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 26,
      "slideType": "appendix_methodology",
      "function": "plan_implementation",
      "notes": "The diagram illustrates a dose escalation study design with three cohorts leading to the RP2D.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/26",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-26",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 27,
      "slideType": "section_divider",
      "function": "transition",
      "notes": "The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/27",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-27",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes scientific diagrams of molecular pathways and comparative efficacy charts.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/28",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-28",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 29,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide uses three bar charts to compare IMX-110 performance against benchmarks in mouse models.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/29",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-29",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 30,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes a process diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/30",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-30",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 31,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes survival curves (Kaplan-Meier), tumor imaging, and tumor frequency metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/31",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-31",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 32,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/32",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-32",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 33,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes two side-by-side clinical data visualizations (line charts and bar charts) comparing patient outcomes.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/33",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-33",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 34,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/34",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-34",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 35,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart is a conceptual visualization of 100% of patients achieving 4 months mPFS.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/35",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-35",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 36,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "Shows two parallel clinical tracks: monotherapy and combination with tislelizumab.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/36",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-36",
      "loopMatches": [
        {
          "to": 36,
          "from": 22,
          "name": "Pareto Focus",
          "slug": "50-pareto-focus",
          "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
          "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
          "evidence": "Presentation of market data and clinical development plan",
          "position": 1,
          "objective": "Focusing on key markets and opportunities",
          "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
          "confidence": 0.7,
          "description": "Show that 80% of results come from 20% of causes to drive prioritization"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 22,
          "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Discussion of market opportunity and clinical development plan",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 37,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/37",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-37",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 49,
          "from": 37,
          "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Overview of Immix Biopharma's technology and pipeline",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 38,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a process-oriented layout to connect platform capabilities to specific product outputs.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/38",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-38",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 49,
          "from": 37,
          "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Overview of Immix Biopharma's technology and pipeline",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 39,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a process-like flow from the 3 pillars to the specific product applications.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/39",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-39",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 49,
          "from": 37,
          "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Overview of Immix Biopharma's technology and pipeline",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 40,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes technical diagrams of the drug construct, comparative histology, and survival curves.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/40",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-40",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 49,
          "from": 37,
          "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Overview of Immix Biopharma's technology and pipeline",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 41,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes two sets of charts: tumor volume line graphs and survival curves. References Abouzeid et al. (2013/2014).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/41",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-41",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 49,
          "from": 37,
          "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Overview of Immix Biopharma's technology and pipeline",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 42,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes detailed scientific diagrams and references to clinical studies.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/42",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-42",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 49,
          "from": 37,
          "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Overview of Immix Biopharma's technology and pipeline",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 43,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/43",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-43",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 49,
          "from": 37,
          "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Overview of Immix Biopharma's technology and pipeline",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 44,
      "slideType": "team_bio",
      "function": "other",
      "notes": "The slide uses a grid-like layout to present headshots, names, titles, and institutional logos for advisory board members.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/44",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-44",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 49,
          "from": 37,
          "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Overview of Immix Biopharma's technology and pipeline",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 45,
      "slideType": "team_bio",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/45",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-45",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 49,
          "from": 37,
          "beatId": "64f12795-5d10-4e4a-9256-051ac9af21d7",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Overview of Immix Biopharma's technology and pipeline",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}